Method and kit for detection of dengue virus
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsJ. Robert Putnak, Kenneth Eckels, Doria R. Dubois, Kevin Cassidy
Life of this patent
Estimating the term…
Abstract
An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models. Uses of the inactivated dengue virus for detecting antibodies to dengue and kits therefor are also described.
Claims8
A method for detecting an antibody directed against a dengue virus antigen comprising:
- (i) incubating a sample suspected of containing anti-dengue antibodies with purified inactivated dengue virus wherein said inactivated dengue virus is one or more purified inactivated dengue virus selected from the group consisting of dengue virus type 1 having accession no. VR-2649, dengue virus type 2 having accession no. VR-2650, dengue virus type 3 having accession no. VR-2654, and dengue virus type 4 having accession no. VR-2651 under conditions which allow the formation of an antibody-inactivated virus complex;
- and
- (ii) detecting said antibody by detecting the antibody-inactivated virus complex.
A diagnostic kit for the detection of antibodies against dengue virus antigens in a sample, said kit comprising one or more purified, inactivated dengue virus selected from the group consisting of dengue virus type 1 having accession no. VR-2649, dengue virus type 2 having accession no. VR-2650, dengue virus type 3 having accession no. VR-2654, and dengue virus type 4 having accession no. VR-2651, for use in detecting said antibodies.
Dependencies are inferred from the claim text.